Table 1 Extracted data from eligible included papers
First author | Type-study | Year | Country | Age Range (years) | Sample size (n) | Prevalence (%) | Analysis of laboratory test | HCT or HB levels | NOS scores |
|---|---|---|---|---|---|---|---|---|---|
Miller et al. [18] | Cross-sectional | 2005 | USA | 17–45 (25.0 ± 6.4) | 214 | 38.60 | Hematocrit (HCT) | - | 7 |
Sabel et al. [16] | Cross-sectional | 2013 | Germany | 17–65 | 53 | 83 | Hematocrit (HCT) | HCT < 37% | 9 |
Misra et al. [19] | Cross-sectional | 2015 | USA | 15.86 ± 1.6 | 60 | 22 | Hematocrit (HCT) | HCT < 37% | 7 |
Guinhut et al. [20] | retrospective observational | 2021 | France | 15–65 (28.7 ± 10.7) | 354 | 79 | Hemoglobin (HB) | HB < 13 g/dl for male HB < 12 g/dl for female | 10 |
Filippo et al. [17] | Cross-sectional | 2016 | Italy | 14–47 (20.4 ± 5.6) | 318 | 16.70 | Hemoglobin (HB) | HB < 12 g/dl | 10 |
DEVUYST et al. [21] | case-control | 1993 | Belgium | 10–30 (18.7 ± 3.8) | 67 | 27 | Hemoglobin (HB) | HB < 120gr/l | 6 |
Mohammedsaeed et al. [22] | Cross-sectional | 2024 | Saudi Arabia | 18–50 | 18 | 72.20 | Hemoglobin (HB) | HB < 12gr/dl | 10 |
Nagata et al. [23] | retrospective observational | 2024 | USA | 9–25 | 373 | 19.30 | Hemoglobin (HB) | HB < 11.8gr/dl | 10 |
Nagata et al. [23] | retrospective observational | 2024 | USA | 9–25 | 55 | 56.36 | Hemoglobin (HB) | HB < 13.6gr/dl | 11 |